Join
Live feed
·
PRReleasevia Quantisnow
Oric Pharmaceuticals Inc. logo

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

ByQuantisnow·Wall Street's wire, on your screen.
ORIC· Oric Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ORIC (Oric Pharmaceuticals Inc.) and more on Quantisnow.